Talimogene Laherparepvec联合Ipilimumab对比Ipilimumab单药治疗晚期不可切除黑色素瘤的随机开放II期研究
联合组内脏病灶缩小者占52%,单药组占23%。研究达到主要终点,联合治疗抗肿瘤活性更高且未增加安全性顾虑。
要点
- 联合组内脏病灶缩小者占52%,单药组占23%,提示疗效不限于注射病灶。
- 联合组≥3级不良事件发生率为45%,单药组为35%;联合组3例致命不良事件均与治疗无关。
核心结论
- 研究达到主要终点,T-VEC联合Ipilimumab的客观缓解率显著高于Ipilimumab单药。
- 数据表明联合治疗抗肿瘤活性更强,且与Ipilimumab单药相比未增加安全性顾虑。
研究设计与样本
- 患者按1:1随机分配至T-VEC联合Ipilimumab组(n=98)或Ipilimumab单药组(n=100)。
- 入组条件:不可切除IIIB-IV期黑色素瘤;BRAF野生型既往治疗不超过1种,BRAF突变型不超过2种;有可测量/可注射病灶;无有症状的自身免疫病或临床显著免疫抑制。
- 主要终点为研究者按免疫相关疗效标准评估的客观缓解率。
主要发现
- 联合组52%和单药组23%的患者观察到内脏病灶缩小。
- 常见不良事件:乏力(联合组59% vs 单药组42%)、寒战(联合组53% vs 单药组3%)、腹泻(联合组42% vs 单药组35%)。
- ≥3级不良事件发生率联合组45% vs 单药组35%。
- 联合组3例患者发生致命不良事件,均与治疗无关。
关键数值与推荐
- T-VEC给药:第1周起始,首剂≤4 mL×10^6 PFU/mL;3周后≤4 mL×10^8 PFU/mL,每2周一次。
- Ipilimumab给药:3 mg/kg每3周一次,最多4剂;单药组第1周开始,联合组第6周开始。
临床怎么用
- 对于晚期不可切除黑色素瘤患者,T-VEC联合Ipilimumab较Ipilimumab单药可提高客观缓解率,且未增加新的安全性顾虑。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose We evaluated the combination of talimogene laherparepvec plus ipilimumab versus ipilimumab alone in patients with advanced melanoma in a phase II study. To our knowledge, this was the first randomized trial to evaluate addition of an oncolytic virus to a checkpoint inhibitor. Methods Patients with unresectable stages IIIB to IV melanoma, with no more than one prior therapy if BRAF wild-type, no more than two prior therapies if BRAF mutant, measurable/injectable disease, and without symptomatic autoimmunity or clinically significant immunosuppression were randomly assigned 1:1 to receive talimogene laherparepvec plus ipilimumab or ipilimumab alone. Talimogene laherparepvec treatment began in week 1 (first dose, ≤ 4 mL × 106 plaque-forming units/mL; after 3 weeks, ≤ 4 mL × 108 plaque-forming units/mL every 2 weeks). Ipilimumab (3 mg/kg every 3 weeks; up to four doses) began week 1 in the ipilimumab alone arm and week 6 in the combination arm. The primary end point was objective response rate evaluated by investigators per immune-related response criteria. Results One hundred ninety-eight patients were randomly assigned to talimogene laherparepvec plus ipilimumab (n = 98), or ipilimumab alone (n = 100). Thirty-eight patients (39%) in the combination arm and 18 patients (18%) in the ipilimumab arm had an objective response (odds ratio, 2.9; 95% CI, 1.5 to 5.5; P = .002). Responses were not limited to injected lesions; visceral lesion decreases were observed in 52% of patients in the combination arm and 23% of patients in the ipilimumab arm. Frequently occurring adverse events (AEs) included fatigue (combination, 59%; ipilimumab alone, 42%), chills (combination, 53%; ipilimumab alone, 3%), and diarrhea (combination, 42%; ipilimumab alone, 35%). Incidence of grade ≥ 3 AEs was 45% and 35%, respectively. Three patients in the combination arm had fatal AEs; none were treatment related. Conclusion The study met its primary end point; the objective response rate was significantly higher with talimogene laherparepvec plus ipilimumab versus ipilimumab alone. These data indicate that the combination has greater antitumor activity without additional safety concerns versus ipilimumab.
引用
- Chesney J, Puzanov I, Collichio F, et al. Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma. J Clin Oncol. 2017. PMID: 28981385. doi:10.1200/JCO.2017.73.7379
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。